Mia-PaCa 2 / Mia-PaCa 2-luc Orthotopic Mouse Model Service for Pancreas Cancer

The Mia-PaCa 2 / Mia-PaCa 2-luc orthotopic mouse model places one of the most aggressive human pancreatic ductal adenocarcinoma cell lines into its organ of origin, where tumors invade locally, spread along nerves, and seed distant metastases much as they do in patients. Alfa Cytology is a preclinical oncology CRO with demonstrated proficiency in orthotopic pancreas cancer modeling. Alfa Cytology offers complete Mia-PaCa 2 / Mia-PaCa 2-luc orthotopic model services, spanning authenticated cell expansion, luciferase reporter verification, surgical or ultrasound-guided implantation, longitudinal in vivo imaging, and thorough endpoint characterization.

Overview of Mia-PaCa 2 / Mia-PaCa 2-luc Orthotopic Mouse Model for Pancreas Cancer

MIA PaCa-2 is one of the most widely used human pancreatic ductal adenocarcinoma (PDAC) cell lines. It was established in 1975 by A. Yunis and colleagues from the tumor of a 65-year-old Caucasian man and grows as an adherent, epithelial-like monolayer with a doubling time of roughly 26 hours. The line is genetically distinctive: it carries a homozygous activating KRAS^G12C mutation — a codon 12 substitution found in only a minority of pancreatic tumors — together with the gain-of-function TP53^R248W mutation and a homozygous deletion of CDKN2A/p16^INK4A, while SMAD4 remains wild-type. This mutational profile, combined with rapid proliferation, strong soft-agar clonogenicity, and elevated PI3K/AKT pathway activity, has made MIA PaCa-2 a workhorse for pancreatic cancer biology and drug screening, and a model of particular interest for testing KRAS G12C-directed inhibitors.

Fig 1. An orthotopic model was established in BALB/c nude mice by injecting MIA PaCa-2 cells (resuspended in Matrigel) into the pancreatic parenchyma; probe specificity was subsequently verified using IVIS after confirming pancreatic tumor growth. (Ren, Han, et al., 2022)

Orthotopically implanted into the pancreas of immunodeficient mice, MIA PaCa-2 cells engraft with essentially 100% efficiency and generate poorly differentiated, highly infiltrative tumors that reproduce hallmark features of human PDAC, including perineural invasion that reaches 100% within eight weeks and dissemination to regional and distant sites. Luciferase-labeled Mia-PaCa 2-luc cells permit whole-body, non-invasive quantification of tumor burden by in vivo bioluminescence imaging, an essential capability for deeply seated pancreatic tumors that calipers cannot measure. Taken together, the Mia-PaCa 2 / Mia-PaCa 2-luc orthotopic model offers a faithful and technically tractable platform for preclinical evaluation of cytotoxic agents, targeted therapies, stromal modulators, and delivery technologies in pancreatic cancer research.

Cell Line Information: Mia-PaCa 2 / Mia-PaCa 2-luc

The defining features of MIA PaCa-2 and its luciferase-labeled derivative Mia-PaCa 2-luc are summarized below, drawing on repository records and peer-reviewed characterizations.

Our Services

Alfa Cytology provides comprehensive Mia-PaCa 2 / Mia-PaCa 2-luc orthotopic model services tailored to preclinical pancreatic cancer programs. Our scientists handle authenticated cell expansion, implantation by laparotomy or ultrasound-guided injection, scheduled in vivo bioluminescence imaging, dosing of test articles, and complete endpoint workups including perineural invasion assessment and metastatic lesion scoring — all under rigorous quality control.

Workflow of Mia-PaCa 2 / Mia-PaCa 2-luc Orthotopic Mouse Model Construction

Establishing a Mia-PaCa 2 / Mia-PaCa 2-luc orthotopic model integrates validated cell preparation, precise implantation technique, and quantitative longitudinal imaging. The standard process unfolds as follows.

1. Cell line authentication and expansion: MIA PaCa-2 or Mia-PaCa 2-luc cells are expanded in DMEM-based medium, confirmed by STR profiling and mycoplasma testing, and checked for viability; luciferase expression in Mia-PaCa 2-luc is validated by an in vitro bioluminescence assay.
2. Host preparation: Immunodeficient mice (e.g., athymic nude, NOD-SCID, or NSG), typically 4–8 weeks of age, are acclimatized and randomized in compliance with an approved animal ethics protocol.
3. Inoculum preparation: Log-phase cells are harvested into a sterile single-cell suspension in PBS or saline, commonly 2 × 10⁵ cells in 40 μL per mouse, with viability confirmed immediately before implantation.
4. Orthotopic implantation: The pancreatic parenchyma is accessed by laparotomy, or by minimally invasive ultrasound-guided injection, and the cell suspension is delivered directly into the pancreas; the entry site is checked for reflux to prevent peritoneal seeding artifacts.
5. Post-operative care and recovery: Analgesia is provided and animals are monitored daily until fully recovered, with body weight and clinical condition recorded.
6. Bioluminescence imaging and randomization (Mia-PaCa 2-luc): Following an initial engraftment window, mice receive intraperitoneal D-luciferin and are imaged weekly by in vivo bioluminescence imaging; animals are randomized to treatment arms once signals reach predefined thresholds.
7. Treatment administration (optional): Test compounds, targeted agents (including KRAS G12C inhibitors), biologics, or combination regimens are dosed according to the customized study design.
8. Endpoint analysis: At study termination, necropsy is performed to weigh the primary pancreatic tumor, score metastatic nodules and perineural invasion, collect ascites where present, and process tissues for H&E and immunohistochemistry, followed by statistical analysis and a consolidated final report.

Fig 2. Mia-PaCa 2 / Mia-PaCa 2-luc orthotopic mouse model construction workflow.

Case Study-Mia-PaCa 2 / Mia-PaCa 2-luc Orthotopic Mouse Model Development

Alfa Cytology has applied the Mia-PaCa 2 / Mia-PaCa 2-luc orthotopic platform in a variety of preclinical research projects, assisting clients with model set-up and quality verification, longitudinal in vivo efficacy testing of single agents and combinations, and detailed endpoint characterization of locally invasive and metastatic disease. Study configurations and data deliverables are adapted to each client’s specific objectives and reporting requirements.

Why Choose Alfa Cytology?

Alfa Cytology combines meticulous model craftsmanship with responsive project management to make your Mia-PaCa 2 / Mia-PaCa 2-luc orthotopic study a success. Key advantages include:

• Rigorously authenticated MIA PaCa-2 cells with confirmed KRAS^G12C and TP53^R248W status, mycoplasma clearance, and verified luciferase reporters.
• Choice of implantation techniques, including microsurgical laparotomy and minimally invasive ultrasound-guided injection, both delivering ~100% engraftment.
• Quantitative in vivo bioluminescence workflows for sensitive, serial measurement of tumor burden in deeply seated pancreatic tumors.
• KRAS G12C-relevant applications, supporting preclinical evaluation of G12C inhibitors and rational combination strategies.
• Detailed invasion-focused endpoints, including perineural invasion scoring, metastatic nodule enumeration, and H&E/IHC histopathology.
• Flexible study designs and dedicated support, with transparent timelines and scientist-level communication from start to finish.

Contact Us

Eager to advance your pancreatic cancer program with a proven orthotopic model? Contact us today to discuss how the Mia-PaCa 2 / Mia-PaCa 2-luc platform can serve your preclinical objectives, or reach out to us for a personalized proposal and timeline. Alfa Cytology is committed to powering your next discovery.

For research use only. Not intended for any clinical use.